MedTrace Logo

Analysis of Aqueous and Vitreous Humor

NCT02067013 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2017-03-01

No results posted yet for this study

Summary

Clinical Retina research studies often collect aqueous samples in hopes of estimating levels of drug or cytokines in the vitreous. Little is known about how well vitreous and aqueous correlate. This study will collect vitreous and aqueous samples at the same time to evaluate and compare drug and cytokine levels.

The overall objective of this study is to evaluate the molecular concentration of growth factors, cytokines and chemokines in human aqueous humor and vitreous samples collected from individuals undergoing pars plana vitrectomy for tractional retinal detachment secondary to proliferative diabetic retinopathy, exudative or tractional retinal detachment secondary to macular degeneration, macular hole or neovascular glaucoma.

Conditions

  • Proliferative Diabetic Retinopathy
  • Macular Degeneration
  • Macular Hole
  • Neovascular Glaucoma

Interventions

DRUG

Ranibizumab

Subjects in the Ranibizumab arm will receive an injection of drug within 2 weeks prior to their surgery.

OTHER

No Ranibizumab

Subjects in the control arm will NOT receive an injection of drug within 2 weeks prior to their surgery.

Sponsors & Collaborators

  • California Retina Consultants

    lead OTHER

Principal Investigators

  • Robert L Avery, MD · California Retina Consultants

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2017-07-31
Completion
2017-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02067013 on ClinicalTrials.gov